Abstract:Human microbiomes, particularly in the gut, could have a major impact on the efficacy and toxicity of drugs. However, gut microbial metabolism is often neglected in the drug discovery and development process. Medicen, a Paris-based human health innovation cluster, has gathered more than 30 international leading experts from pharma, academia, biotech, clinical research organizations, and regulatory science to develop proposals to facilitate the integration of microbiome science into drug discovery and development. Seven subteams were formed to cover the complementary expertise areas of 1) pharma experience and case studies, 2) in silico microbiome–drug interaction, 3) in vitro microbial stability screening, 4) gut fermentation models, 5) animal models, 6) microbiome integration in clinical and regulatory aspects, and 7) microbiome ecosystems and models. Each expert team produced a state-of-the-art report of their respective field highlighting existing microbiome-related tools at every stage of drug discovery and development. The most critical limitations are the growing, but still limited, drug–microbiome interaction data to produce predictive models and the lack of agreed-upon standards despite recent progress. In this paper we will report on and share proposals covering 1) how microbiome tools can support moving a compound from drug discovery to clinical proof-of-concept studies and alert early on potential undesired properties stemming from microbiome-induced drug metabolism and 2) how microbiome data can be generated and integrated in pharmacokinetic models that are predictive of the human situation. Examples of drugs metabolized by the microbiome will be discussed in detail to support recommendations from the working group. SIGNIFICANCE STATEMENT Gut microbial metabolism is often neglected in the drug discovery and development process despite growing evidence of drugs' efficacy and safety impacted by their interaction with the microbiome. This paper will detail existing microbiome-related tools covering every stage of drug discovery and development, current progress, and limitations, as well as recommendations to integrate them into the drug discovery and development process.

Identifying and Filling the Chemobiological Gaps of Gut Microbial Metabolites

Computational Analysis of the Gut Microbiota-Mediated Drug Metabolism

A metabolomics pipeline for the mechanistic interrogation of the gut microbiome

How Do Microbial Metabolites Interact with Their Protein Targets?

Advances in the integration of metabolomics and metagenomics for human gut microbiome and their clinical applications

Exploring substrate–microbe interactions: a metabiotic approach toward developing targeted synbiotic compositions

Gut microbial metabolites as multi-kingdom intermediates

Gut Microbiota Profiling: Metabolomics Based Approach to Unravel Compounds Affecting Human Health

The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs

Systematic mapping of drug metabolism by the human gut microbiome

Emerging Targetome and Signalome Landscape of Gut Microbial Metabolites

Metabolites: a converging node of host and microbe to explain meta-organism

FROM MICROBIOME TO METABOLOME

High Throughput and Quantitative Measurement of Microbial Metabolome by Gas Chromatography/Mass Spectrometry Using Automated Alkyl Chloroformate Derivatization.

Personalized Mapping of Drug Metabolism by the Human Gut Microbiome

Microbiome metabolite quantification methods enabling insights into human health and disease

Metabolomics approaches for characterizing metabolic interactions between host and its commensal microbes.

Advancing functional and translational microbiome research using meta-omics approaches

G protein-coupled receptors: A target for microbial metabolites and a mechanistic link to microbiome-immune-brain interactions

Mapping human microbiome drug metabolism by gut bacteria and their genes

Gut Microbiome Integration in Drug Discovery and Development of Small Molecules